FXR2 (FMR1 autosomal homolog 2) activators belong to a distinctive class of chemical compounds that exert their influence on the FXR2 protein, a member of the fragile X mental retardation (FMR) family. The FMR proteins play a crucial role in synaptic plasticity and neuronal development. FXR2, in particular, shares sequence homology with the FMR1 and FXR1 proteins, collectively contributing to the regulation of mRNA translation in neurons. The activation of FXR2 involves intricate molecular interactions and conformational changes that modulate its functional role in RNA metabolism. Structurally, these activators are designed to bind to specific sites on the FXR2 protein, inducing a cascade of events that may enhance its regulatory capabilities within cellular processes. Understanding the detailed mechanisms of FXR2 activation at the molecular level is paramount for unraveling the complexities of neurodevelopmental pathways and synaptic function.
Moreover, the development and study of FXR2 activators contribute to advancing our knowledge of post-transcriptional gene regulation, with potential implications for various cellular functions beyond the nervous system. As researchers delve into the structural nuances and biochemical intricacies of these compounds, they aim to decipher the broader implications of FXR2 activation in cellular contexts. The exploration of FXR2 activators not only sheds light on the intricate regulatory networks governing neuronal processes but also holds promise for uncovering novel insights into the broader landscape of cellular biology, with potential applications extending beyond the realm of neurological disorders.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor commonly used in research to study cell growth and proliferation. Acts by inhibiting the mTOR pathway, potentially activating FXR2 indirectly through its role in protein synthesis activation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
An analog of rapamycin, also an mTOR inhibitor used for immunosuppression and anti-cancer therapy. Like rapamycin, it may indirectly activate FXR2 through mTOR pathway modulation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
Activator of AMP-activated protein kinase (AMPK), a cellular energy sensor. Potential indirect activation of FXR2 through pathways associated with energy homeostasis and protein synthesis. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase (HDAC) inhibitor impacting gene expression. May indirectly activate FXR2 by influencing the epigenetic regulation of genes involved in its expression or function. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Inhibitor of protein phosphatases, impacting phosphorylation events. May indirectly activate FXR2 by modulating signaling pathways related to its post-translational activations. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
Small molecule Wnt agonist influencing the Wnt signaling pathway. May indirectly activate FXR2 through signaling cascades related to Wnt pathways involved in neural development. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
Small molecule Wnt inhibitor, modulating the Wnt signaling pathway. May indirectly activate FXR2 through regulatory networks associated with Wnt signaling in cellular processes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor affecting protein degradation pathways. May indirectly activate FXR2 levels by altering the turnover of proteins involved in its activation or stability. |